Özge Kama Başci, Arzu Yorgancioglu, Soner Gunes, Cengiz Kirmaz
{"title":"MASK-air®应用于接受免疫治疗的变应性鼻炎患者的可行性及其对生活质量的影响。","authors":"Özge Kama Başci, Arzu Yorgancioglu, Soner Gunes, Cengiz Kirmaz","doi":"10.15586/aei.v53i3.1208","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>The aim of MASK-air<sup>®</sup> application is to enhance awareness of allergic rhinitis (AR) and its complications, thereby reducing the risk of developing asthma.</p><p><strong>Objective: </strong>The aims of this study were to evaluate the impact of MASK-air<sup>®</sup> on the quality of life (QoL) and symptomatology of AR patients undergoing allergen immunotherapy (AIT). The study also evaluated patient satisfaction with the application.</p><p><strong>Materials and methods: </strong>A prospective cross-sectional study was conducted between August and November 2019 at a tertiary Allergy and Immunology center involving patients receiving AIT. Participants were instructed on accessing and utilizing MASK-air<sup>®</sup> daily through face-to-face interviews. Concurrently, the Score for Allergic Rhinitis (SFAR) and the Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ) were administered alongside MASK-air<sup>®</sup> Visual Analog Scale (VAS) scores. After 6 months, RQLQ scores were reassessed and a satisfaction survey was conducted.</p><p><strong>Results: </strong>This study comprised 96 patients. Significant correlations were observed among SFAR, RQLQ, and VAS scores. After 6 months of MASK-air<sup>®</sup> usage, improvements in QoL and symptom reduction were evident. Notably, participants who consistently used MASK-air<sup>®</sup> demonstrated significant reductions in activity limitations and hay fever scores compared to irregular users (p = 0.05 and p = 0.02, respectively). Additionally, participants under 40 years of age and those with higher education levels exhibited a greater inclination toward online monitoring via the application. Overall, participants found MASK-air<sup>®</sup> practical, citing various advantages and disadvantages.</p><p><strong>Conclusion: </strong>MASK-air<sup>®</sup> serves as a valuable tool for physicians in managing treatment and is associated with validated, reliable scales. Its use was linked to enhanced QoL and symptom reduction among participants, irrespective of treatment duration.</p>","PeriodicalId":7536,"journal":{"name":"Allergologia et immunopathologia","volume":"53 3","pages":"106-114"},"PeriodicalIF":2.5000,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Feasibility of MASK-air<sup>®</sup> use in allergic rhinitis patients receiving immunotherapy and the effect on quality of life.\",\"authors\":\"Özge Kama Başci, Arzu Yorgancioglu, Soner Gunes, Cengiz Kirmaz\",\"doi\":\"10.15586/aei.v53i3.1208\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>The aim of MASK-air<sup>®</sup> application is to enhance awareness of allergic rhinitis (AR) and its complications, thereby reducing the risk of developing asthma.</p><p><strong>Objective: </strong>The aims of this study were to evaluate the impact of MASK-air<sup>®</sup> on the quality of life (QoL) and symptomatology of AR patients undergoing allergen immunotherapy (AIT). The study also evaluated patient satisfaction with the application.</p><p><strong>Materials and methods: </strong>A prospective cross-sectional study was conducted between August and November 2019 at a tertiary Allergy and Immunology center involving patients receiving AIT. Participants were instructed on accessing and utilizing MASK-air<sup>®</sup> daily through face-to-face interviews. Concurrently, the Score for Allergic Rhinitis (SFAR) and the Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ) were administered alongside MASK-air<sup>®</sup> Visual Analog Scale (VAS) scores. After 6 months, RQLQ scores were reassessed and a satisfaction survey was conducted.</p><p><strong>Results: </strong>This study comprised 96 patients. Significant correlations were observed among SFAR, RQLQ, and VAS scores. After 6 months of MASK-air<sup>®</sup> usage, improvements in QoL and symptom reduction were evident. Notably, participants who consistently used MASK-air<sup>®</sup> demonstrated significant reductions in activity limitations and hay fever scores compared to irregular users (p = 0.05 and p = 0.02, respectively). Additionally, participants under 40 years of age and those with higher education levels exhibited a greater inclination toward online monitoring via the application. Overall, participants found MASK-air<sup>®</sup> practical, citing various advantages and disadvantages.</p><p><strong>Conclusion: </strong>MASK-air<sup>®</sup> serves as a valuable tool for physicians in managing treatment and is associated with validated, reliable scales. Its use was linked to enhanced QoL and symptom reduction among participants, irrespective of treatment duration.</p>\",\"PeriodicalId\":7536,\"journal\":{\"name\":\"Allergologia et immunopathologia\",\"volume\":\"53 3\",\"pages\":\"106-114\"},\"PeriodicalIF\":2.5000,\"publicationDate\":\"2025-05-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Allergologia et immunopathologia\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.15586/aei.v53i3.1208\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/1/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"Q3\",\"JCRName\":\"ALLERGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Allergologia et immunopathologia","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.15586/aei.v53i3.1208","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q3","JCRName":"ALLERGY","Score":null,"Total":0}
Feasibility of MASK-air® use in allergic rhinitis patients receiving immunotherapy and the effect on quality of life.
Background: The aim of MASK-air® application is to enhance awareness of allergic rhinitis (AR) and its complications, thereby reducing the risk of developing asthma.
Objective: The aims of this study were to evaluate the impact of MASK-air® on the quality of life (QoL) and symptomatology of AR patients undergoing allergen immunotherapy (AIT). The study also evaluated patient satisfaction with the application.
Materials and methods: A prospective cross-sectional study was conducted between August and November 2019 at a tertiary Allergy and Immunology center involving patients receiving AIT. Participants were instructed on accessing and utilizing MASK-air® daily through face-to-face interviews. Concurrently, the Score for Allergic Rhinitis (SFAR) and the Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ) were administered alongside MASK-air® Visual Analog Scale (VAS) scores. After 6 months, RQLQ scores were reassessed and a satisfaction survey was conducted.
Results: This study comprised 96 patients. Significant correlations were observed among SFAR, RQLQ, and VAS scores. After 6 months of MASK-air® usage, improvements in QoL and symptom reduction were evident. Notably, participants who consistently used MASK-air® demonstrated significant reductions in activity limitations and hay fever scores compared to irregular users (p = 0.05 and p = 0.02, respectively). Additionally, participants under 40 years of age and those with higher education levels exhibited a greater inclination toward online monitoring via the application. Overall, participants found MASK-air® practical, citing various advantages and disadvantages.
Conclusion: MASK-air® serves as a valuable tool for physicians in managing treatment and is associated with validated, reliable scales. Its use was linked to enhanced QoL and symptom reduction among participants, irrespective of treatment duration.
期刊介绍：
Founded in 1972 by Professor A. Oehling, Allergologia et Immunopathologia is a forum for those working in the field of pediatric asthma, allergy and immunology. Manuscripts related to clinical, epidemiological and experimental allergy and immunopathology related to childhood will be considered for publication. Allergologia et Immunopathologia is the official journal of the Spanish Society of Pediatric Allergy and Clinical Immunology (SEICAP) and also of the Latin American Society of Immunodeficiencies (LASID). It has and independent international Editorial Committee which submits received papers for peer-reviewing by international experts. The journal accepts original and review articles from all over the world, together with consensus statements from the aforementioned societies. Occasionally, the opinion of an expert on a burning topic is published in the "Point of View" section. Letters to the Editor on previously published papers are welcomed. Allergologia et Immunopathologia publishes 6 issues per year and is included in the major databases such as Pubmed, Scopus, Web of Knowledge, etc.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
